Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095 25/09/2026

113,90 USD (-1,15%)

(-1,15%) 25/09/2026

Grafiek Halozyme Therapeutics Inc.

Grafiek Halozyme Therapeutics Inc.

1 dag1d -1,15%
1 week1w 2,20%
1 maand1m 6,53%
3 maanden3m 47,58%
6 maanden6m 84,81%
1 jaar1j 55,41%
5 jaar5j 183,69%

Halozyme Therapeutics Inc. in het nieuws

Toon enkel gratis nieuws

18 september 2026 · Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 · Persbericht

16 september 2026 · Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 · Persbericht

2 september 2026 · Halozyme to Participate at Upcoming Investor Conferences · Persbericht

18 augustus 2026 · Halozyme Appoints Dannielle Appelhans to its Board of Directors · Persbericht

6 augustus 2026 · Halozyme Reports Record Second Quarter 2026 Results, Beats Estimates And Raises Full Year 2026 Financial Guidance · Persbericht

23 juli 2026 · Halozyme to Report Second Quarter 2026 Financial and Operating Results · Persbericht

20 juli 2026 · Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology · Persbericht

30 juni 2026 · Halozyme Appoints David Ramsay as President Drug Delivery · Persbericht

15 juni 2026 · Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 · Persbericht

11 mei 2026 · Halozyme Reports First Quarter 2026 Results And Reiterates 2026 Financial Guidance · Persbericht

Profiel Halozyme Therapeutics Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.halozyme.com

Hoofdzetel: San Diego, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe